SCHEMBL3373634

SCHEMBL3373634

CCOC(=O)C(Cc1ccc(OCc2csc(-c3ccc(C(C)C)cc3)n2)c(F)c1)OCC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.39
PPARG P37231 1/20 0.38
PPARD Q03181 1/20 0.38
PPARA Q07869 1/20 0.38
ALOX5 P09917 2/20 0.38
PSEN1 P49768 1/20 0.38
CACNA1G O43497 1/20 0.38
CACNA1H O95180 1/20 0.38
CACNA1I Q9P0X4 1/20 0.38
SCN9A Q15858 7/20 0.37
KCNH2 Q12809 1/20 0.37
LMNA P02545 2/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
GAA P10253 1/20 0.35
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
TSHR P16473 3/20 0.35
MAPT P10636 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3370374 0.92 PPARA (0.43) FFAR1PPARGPPARDPPARAALOX5
SCHEMBL3369630 0.92 LMNA (0.43) FFAR1PPARGPPARDPPARAALOX5
SCHEMBL3374361 0.92 TP53 (0.38) FFAR1PPARGPPARDPPARACACNA1G
SCHEMBL3372499 0.91 PPARG (0.39) FFAR1PPARGPPARDPPARAALOX5
SCHEMBL3372330 0.91 LMNA (0.38) FFAR1PPARGPPARDPPARACACNA1G
SCHEMBL3374527 0.91 RAB9A (0.44) FFAR1PPARGPPARDPPARALMNA
SCHEMBL3375391 0.89 ALOX5 (0.42) FFAR1PPARGPPARDPPARAALOX5
SCHEMBL3402718 0.89 ALOX5 (0.49) FFAR1PPARGPPARDPPARAALOX5
SCHEMBL3370575 0.87 F2RL3 (0.39) PPARGPPARDPPARAALOX5PSEN1
SCHEMBL3371101 0.87 SCN9A (0.39) ALOX5PSEN1SCN9AKCNH2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537091-B1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS HOFFMANN LA ROCHE (CH) 2010-10-06 EP disclosed
EP-1537091-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2005-06-08 EP disclosed
US-6809110-B2 NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID HOFFMANN-LA ROCHE INC. 2004-10-26 US disclosed
US-20040110807-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-10 US disclosed
WO-2004020420-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110807-A1 Thiazole derivatives SLC5A1, GPR119, INSR FFAR1 32/4885PPARG 181/4885PPARD 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.